ethyl 2-(methoxymethyl)cyclopropanecarboxylate | 29124-03-6

• 英文名称: ethyl 2-(methoxymethyl)cyclopropanecarboxylate
• 英文别名: Ethyl-2-methoxymethylcyclopropan-1-carboxylat；ethyl 2-(methoxymethyl)cyclopropane-1-carboxylate
• CAS: 29124-03-6
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: DKZGIPJBKCIECD-UHFFFAOYSA-N

物化性质

• 沸点：
  179.7±13.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲酰基-1-环丙烷甲酸乙酯 、 碘甲烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 以52%的产率得到ethyl 2-(methoxymethyl)cyclopropanecarboxylate
  参考文献：
  名称：

  [EN] HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
  [FR] COMPOSES HETEROBICYCLIQUES EN TANT QU'AGENTS ACTIFS AU NIVEAU PHARMACEUTIQUE

  摘要：

  公开号：

  WO2005023818A3

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• Facile catalytic methods for intermolecular generation of allylic oxonium ylides and their stereoselective [2,3]- sigmatropic rearrangement
  作者：Michael P. Doyle、Vahid Bagheri、Nancy K. Harn

  DOI：10.1016/s0040-4039(00)80695-4

  日期：1988.1

  Allylic oxonium ylides, generated by rhodium(II) acetate-catalyzed decomposition of diazo carbonyl compounds in the presence of allyl methyl ethers, undergo the [2,3]-sigmatropic rearrangement with a high degree of diastereoselectivity.

  在烯丙基甲基醚存在下，由乙酸铑（II）催化重氮羰基化合物分解生成的烯丙基氧鎓叶立德经历[2,3]-σ重排，具有高度非对映选择性。
• Heterobicyclic Compounds as Pharmaceutically Active Agents
  申请人：Koul Anil

  公开号：US20070275962A1

  公开（公告）日：2007-11-29

  Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.

  本文介绍了异杂双环化合物，例如4,5,6,7-四氢苯并[b]噻吩-3-羧酸酰胺，4,7-二氢-5H-噻吩[2,3-c]硫杂吡喃-3-羧酸酰胺，4,7-二氢-5H-噻吩[2,3-c]吡喃-3-羧酸酰胺，或苯并[b]噻吩-3-羧酸酰胺及其药学上可接受的盐。这些衍生物的用途包括预防和/或治疗各种疾病，如传染性疾病，包括分支杆菌感染和机会性疾病，朊病，免疫性疾病，自身免疫性疾病，双相和临床障碍，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经退行性疾病和中风，以及含有至少一种异杂双环化合物和/或药学上可接受的盐的组合物。此外，还公开了合成异杂双环化合物的反应程序。
• Naphthyridines as inhibitors of HPK1
  申请人：Genentech, Inc.

  公开号：US10407424B2

  公开（公告）日：2019-09-10

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  介绍了萘啶类化合物及其作为 HPK1 抑制剂的用途。这些化合物可用于治疗 HPK1 依赖性疾病和增强免疫反应。还描述了抑制 HPK1 的方法、治疗 HPK1 依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• Reaction of carbethoxycarbene with aliphatic sulfides and allyl compounds
  作者：Wataru Ando、Tomio Yagihara、Suji Kondo、Keiji Nakayama、Hideo Yamato、Setuko Nakaido、Toshihiko Migita

  DOI：10.1021/jo00812a002

  日期：1971.7